8-K: SS Innovations Achieves World's First Intercontinental Robotic Cardiac Telesurgery

SS Innovations International, Inc. announced its CEO successfully completed the world's first intercontinental robotic cardiac telesurgery using the SSi Mantra 3 system, spanning over 4,000 miles from France to India.

Summary

• SS Innovations International, Inc. (Nasdaq: SSII) announced that its Chairman and CEO, Dr. Sudhir Srivastava, successfully completed the world's first intercontinental robotic cardiac telesurgery on July 19, 2025.
• The procedure, a robotic atrial septal defect closure, was performed remotely from Strasbourg, France, to Indore, India, covering a distance of over 4,000 miles.
• The surgery utilized the Company's SSi Mantra 3 surgical robotic system.
• The procedure was completed without technical issues, demonstrating imperceptible latency, flawless precision, and seamless robotic control.
• Patient-side support in Indore was provided by Dr. Lalit Malik, Dr. Ram Krishna Shukla, Dr. Bipin Arya, and the SS Innovations and SAIMS teams.
• The live telesurgery was moderated by Dr. Husam H. Balkhy, President of ISMICS.
• To date, 35 telesurgeries, including 10 cardiac procedures, and a total of 250 cardiac procedures have been successfully completed using the SSi Mantra system.
• Over 5,000 multi-specialty surgeries have been successfully carried out with the SSi Mantra system without any device-related adverse events.

Sentiment

Score: 9

Explanation: The filing announces a significant, world-first achievement in robotic telesurgery, demonstrating advanced capabilities of the company's core product and its potential to revolutionize global healthcare access. The absence of any negative news or risks, coupled with strong performance metrics (5000+ surgeries without adverse events), indicates a highly positive outlook.

Positives

• Successful completion of the world's first intercontinental robotic cardiac telesurgery, a significant technological milestone.
• Demonstration of the SSi Mantra 3 system's advanced capabilities, including imperceptible latency, flawless precision, and seamless robotic control over long distances (4,000+ miles).
• Successful completion of 35 telesurgeries (10 cardiac) and 250 total cardiac procedures with the SSi Mantra system.
• Over 5,000 multi-specialty surgeries performed with the SSi Mantra system without device-related adverse events.
• SS Innovations is the only surgical robotic company to receive regulatory approval from India's CDSCO for both tele proctoring and telesurgery.
• The technology addresses obstacles related to travel, time, cost, and surgical accessibility, potentially democratizing complex cardiac care globally.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied.

Future Outlook

The Company's advanced SSi Mantra surgical robotic technology platform, including its cutting-edge telesurgery capabilities, addresses traditional obstacles related to travel, time, cost, and surgical accessibility, creating a more efficient and equitable medical standard for both patients and surgeons. The Company plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.

Management Comments

• "I would like to extend my gratitude to Dr. Vipul Patel, M.D., F.A.C.S., Chairman of the Society of Robotic Surgery for this opportunity at the SRS 2025 Conference, Dr. Mohit Bhandari, the IRCAD India team, and the entire SS Innovations team whose dedication and innovation made the worlds first intercontinental robotic cardiac telesurgery possible."
• "This historic achievement not only demonstrates the advanced capabilities of our SSi Mantra 3 surgical robotic system but also further paves the way for redefining and democratizing global delivery of complex cardiac care, especially in regions with limited access to surgical expertise."

Industry Context

This achievement represents a significant leap in medical technology, particularly in the field of robotic surgery and telemedicine. It demonstrates the potential for remote surgical procedures to overcome geographical barriers and expand access to specialized medical expertise globally, aligning with broader trends towards digital health and decentralized care.

Comparison to Industry Standards

• SS Innovations is the only surgical robotic company to have received regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for both tele proctoring and telesurgery.
• The successful completion of a robotic atrial septal defect closure over 4,000 miles with imperceptible latency and flawless precision sets a new benchmark for intercontinental telesurgery, surpassing previous remote surgery distances and demonstrating robust system reliability for complex cardiac procedures.
• The SSi Mantra system has successfully completed over 5,000 multi-specialty surgeries without any device-related adverse events, indicating a strong safety profile compared to general industry standards for new surgical robotic platforms.

Stakeholder Impact

• Shareholders: Positive impact due to significant technological achievement, potential for increased market share, and enhanced company reputation.
• Patients: Improved access to complex cardiac care, especially in regions with limited surgical expertise, and potentially more efficient and equitable medical standards.
• Surgeons: Enhanced capabilities through advanced robotic systems and telesurgery, allowing for remote collaboration and expanded reach.
• Employees: Positive impact from being part of a company achieving a world-first milestone, potentially leading to increased morale and opportunities.

Next Steps

• Expand the global presence of the SSi Mantra surgical robotic solutions.

Key Dates

Recommendation

The successful completion of the world's first intercontinental robotic cardiac telesurgery represents a monumental technological leap for SS Innovations International, Inc. This achievement validates the SSi Mantra 3 system's advanced capabilities, reliability, and potential to democratize complex surgical care globally. The company's unique regulatory approval in India for telesurgery further solidifies its competitive advantage. This breakthrough significantly enhances the company's market position, credibility, and long-term growth prospects in the rapidly expanding robotic surgery market, making it a highly attractive investment.

Keywords

Robotic Surgery, Telesurgery, Cardiac Surgery, SSi Mantra, Medical Technology, Healthcare Innovation, Surgical Robotics, Intercontinental Surgery, SS Innovations International